Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Novel GLP-1 receptor agonists for diabetes.

Garber AJ.

Expert Opin Investig Drugs. 2012 Jan;21(1):45-57. doi: 10.1517/13543784.2012.638282. Epub 2011 Nov 24. Review.

PMID:
22111970
2.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
3.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
4.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
5.

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.

Madsbad S.

Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29. Review.

6.

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.

Montanya E.

Expert Opin Pharmacother. 2012 Jul;13(10):1451-67. doi: 10.1517/14656566.2012.692777. Review.

PMID:
22725703
7.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
8.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
9.
10.

Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.

Stonehouse A, Walsh B, Cuddihy R.

Diabetes Technol Ther. 2011 Oct;13(10):1063-9. doi: 10.1089/dia.2011.0076. Epub 2011 Jul 6. Review.

11.

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

Neumiller JJ.

Clin Ther. 2011 May;33(5):528-76. doi: 10.1016/j.clinthera.2011.04.024. Review.

PMID:
21665041
12.

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

Shaefer CF Jr, Kushner P, Aguilar R.

Postgrad Med. 2015;127(8):818-26. doi: 10.1080/00325481.2015.1090295. Epub 2015 Sep 15. Review.

PMID:
26371721
13.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
14.

Liraglutide for the treatment of type 2 diabetes: a clinical update.

Peters KR.

Am J Ther. 2013 Mar-Apr;20(2):178-88. doi: 10.1097/MJT.0b013e3182204c16. Review.

PMID:
21734532
15.

Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.

Spellman CW.

J Am Osteopath Assoc. 2012 Jan;112(1 Suppl 1):S7-15. Review.

PMID:
22267302
16.

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.

Tzefos M, Olin JL.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1294-300. doi: 10.1345/aph.1P047. Epub 2010 Jun 8. Review.

PMID:
20530705
17.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
18.

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Blonde L, Montanya E.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:20-32. doi: 10.1111/j.1463-1326.2012.01575.x. Review.

PMID:
22405266
19.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.

BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. Review.

20.

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.

Verge D, López X.

Curr Diabetes Rev. 2010 Jul;6(4):191-200. Review.

PMID:
20380625

Supplemental Content

Support Center